Synapse - Works

Results (5608)

EV-201: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy

Meeting Abstract

Rosenberg, J. E.; Balar, A.; O'Donnell, P. H.; Heath, E. I.; Hahn, N. M.; Cavazos, N. M.; Melhem-Bertrandt, A.; Petrylak, D. P.
Annals of Oncology (2018)

Fulltext@MSK | Save

Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1 mg/kg + ipilimumab 3 mg/kg expansion from CheckMate 032

Meeting Abstract

Rosenberg, J. E.; Sharma, P.; de Braud, F. G. M.; Basso, U.; Calvo, E.; Bono, P.; Morse, M.; Ascierto, P. A.; Lopez-Martin, J. A.; Brossart, P.; more...
Annals of Oncology (2018)

Fulltext@MSK | Save

BAYOU: Phase II study of efficacy and safety of durvalumab plus olaparib as first-line therapy in cisplatin-ineligible patients (pts) with stage iv urothelial cancer (UC)

Meeting Abstract

Rosenberg, J. E.; Bajorin, D. F.; Smith, A.; D'Cruz, C.; Lanasa, M.
Annals of Oncology (2018)

Fulltext@MSK | Save

Phase Ib KEYNOTE-200: A study of an intravenously delivered oncolytic virus, coxsackievirus A21 in combination with pembrolizumab in advanced NSCLC and bladder cancer patients

Meeting Abstract

Rudin, C. M.; Pandha, H. S.; Gupta, S.; Zibelman, M. R.; Akerley, W.; Day, D.; Hill, A. G.; Sanborn, R. E.; O'Day, S. J.; Clay, T. D.; more...
Annals of Oncology (2018)

Fulltext@MSK | Save

EV-301: An open-label, randomized phase III study to evaluate enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC)

Meeting Abstract

Petrylak, D. P.; Rosenberg, J.; Duran, I.; Loriot, Y.; Sonpavde, G.; Wu, C.; Gartner, E.; Melhem-Bertrandt, A.; Powles, T.
Annals of Oncology (2018)

Fulltext@MSK | Save

Responses and durability of clinical benefit in triple negative breast cancer patients treated with pegilodecakin monotherapy or in combination with platinum plus taxane-based chemotherapy

Meeting Abstract

Naing, A.; Autio, K. A.; Falchook, G. S.; Meric-Bernstam, F.; Litton, J. K.; Ibrahim, N. K.; Hung, A.; Oft, M.; Leveque, J.; Patel, M. R.
Annals of Oncology (2018)

Fulltext@MSK | Save

CTC-based biomarkers & PSMA-targeted imaging in patients with metastatic castrate-resistant prostate cancer (mCRPC)

Meeting Abstract

Morris, M. J.; Vogelzang, N. J.; Sartor, O.; Armour, A.; Messmann, R.; Groaning, M.; Robarts, A.; Tolcher, A. W.; Gordon, M.; Babiker, H. M.; more...
Annals of Oncology (2018)

Fulltext@MSK | Save

Correlative analyses of serum biomarkers and efficacy outcomes in the randomized phase II trial of lenvatinib (LEN), everolimus (EVE), or LEN+EVE in patients with metastatic renal cell carcinoma

Meeting Abstract

Lee, C. H.; Motzer, R. J.; Glen, H.; Michaelson, M. D.; Larkin, J.; Minoshima, Y.; Kanekiyo, M.; Dairiki, R.; Sachdev, P.; Dutcus, C. E.; more...
Annals of Oncology (2018)

Fulltext@MSK | Save

Biological features and clinical outcomes in atezolizumab (atezo)-treated patients (pts) with metastatic urothelial cancer (mUC) of the upper vs lower urinary tract (UTUC vs LTUC)

Meeting Abstract

Galsky, M. D.; Banchereau, R.; Kadel, E. E. 3rd; Ramirez-Montagut, T.; Mariathasan, S.; Thåström, A.; Rosenberg, J.; Powles, T.; van der Heijden, M. S.; Necchi, A.
Annals of Oncology (2018)

Fulltext@MSK | Save

Overall survival (OS) implications for patients with mCRPC through coverage and adoption of nuclear AR-V7 testing by healthcare systems

Meeting Abstract

Hornberger, J.; Graf, R. P.; Hulling, M.; Attard, G.; Allan, A.; Dittamore, R.; Scher, H. I.
Annals of Oncology (2018)

Fulltext@MSK | Save